IDEXX Laboratories (NASDAQ:IDXX) Shares Gap Up Following Strong Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $551.21, but opened at $625.00. IDEXX Laboratories shares last traded at $643.2080, with a volume of 380,773 shares changing hands.

The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter last year, the company earned $3.22 EPS. IDEXX Laboratories’s revenue for the quarter was up 9.9% compared to the same quarter last year.

IDEXX Laboratories News Roundup

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: IDEXX reported Q3 revenue of about $1.21 billion and EPS of $3.96, both ahead of analyst expectations. Recurring veterinary diagnostics sales were a growth driver, and the company raised its FY2026 EPS outlook to $14.96–$15.16; revenue guidance is $4.7–$4.8 billion. Reuters article
• Positive Sentiment: Morgan Stanley reiterated an Overweight/Buy view and raised its price target to $810 from $805, citing strong execution and the improved outlook. UBS also characterized the results as strong despite a lackluster veterinary-visit environment. Analyst rating article
• Positive Sentiment: Recent technical coverage noted that IDXX moved above its 200-day moving average, a signal some investors interpret as supportive of a longer-term trend. Zacks technical analysis
• Negative Sentiment: Veterinary visits remain lackluster, and coverage flagged a softer margin outlook. These factors could limit growth or profitability even as diagnostics sales and the full-year earnings forecast improve. Motley Fool article

Analysts Set New Price Targets

IDXX has been the topic of a number of research reports. JPMorgan Chase & Co. dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research report on Friday, October 16th. UBS Group lifted their price target on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a research note on Tuesday. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Finally, Barclays cut their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $719.55.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the company. J.Safra Asset Management Corp acquired a new position in IDEXX Laboratories during the 2nd quarter worth $25,000. Elevation Wealth Partners LLC lifted its holdings in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares during the last quarter. Pension & Wealth Management Advisors Inc. bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $29,000. Arlington Trust Co LLC raised its position in IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after purchasing an additional 19 shares during the last quarter. Finally, Bell Investment Advisors Inc raised its position in shares of IDEXX Laboratories by 45.5% in the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock valued at $33,000 after acquiring an additional 20 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.1%

The company has a market capitalization of $52.94 billion, a P/E ratio of 45.32 and a beta of 1.55. The business has a fifty day moving average price of $538.81 and a 200 day moving average price of $573.69. The company has a quick ratio of 0.87, a current ratio of 1.19 and a debt-to-equity ratio of 0.16.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.